Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer immunotherapies that entered the public markets through a de-SPAC merger in 2022. The transaction involved Brookline Capital Acquisition Corp, sponsored by Brookline Capital Markets, which completed its blank-check IPO in 2021. Operating in the oncology sector, Apexigen filed its Form 10-Q with the SEC in August 2022, covering its first full quarterly reporting period as a combined public entity following the merger close earlier that year. The company's pipeline targets novel antibodies designed to engage the immune system in oncological indications. Sign up on SpacDesk for full filings, sponsor profiles, and deal-level analytics on Apexigen and the broader SPAC universe.